VivoSeq
Oncology

Colorectal Adenocarcinoma

59

Pipeline Programs↗

4

Active Trials↗

29

Companies Involved↗

Colorectal Adenocarcinoma is a moderately active landscape with 59 programs across 29 companies. The most active players are Gynecologic Oncology Group, Imclone, Genzyme, a Sanofi Company. 15 therapies are approved with 11 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

62/100

Pipeline Velocity

11/100

Mech. Concentration

14/100

Completion Rate

61/100

Attrition Rate

27/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Gynecologic Oncology Group

1 program

Phase 1I

Imclone

1 program

Phase 1G

Genzyme, a Sanofi Company

1 program

Phase 1Daiichi Sankyo logo

Daiichi Sankyo

1 program

Phase 2Biogen logo

Biogen

1 program

Phase 2Gilead logo

Gilead

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical4

Panitumumab

Amgen

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Bevacizumab

Bio-Thera Solutions

Aflibercept

Regeneron

Phase 18

Pemetrexed Disodium

Gynecologic Oncology Group

Resveratrol

National Cancer Institute (NCI)

Cetuximab

Imclone

Obinutuzumab

Roche

Tocilizumab

Roche

Phase 221

Gemcitabine

Johnson & Johnson

Antineoplaston A10

Burzynski Research Institute

Pembrolizumab

Merck & Co.

Raltitrexed

Nanjing Chia-tai Tianqing Pharmaceutical

Cabozantinib

Bristol-Myers Squibb

Phase 311

Irinotecan Hydrochloride

Eastern Cooperative Oncology Group

Atezolizumab

Roche

Regorafenib

Bayer

Tegafur

The First Affiliated Hospital with Nanjing Medical University

Capecitabine

Engelhard Arzneimittel GmbH & Co.KG

Approved15

Thalidomide

Bristol-Myers Squibb

Floxuridine

Pfizer

Paclitaxel

Teva

Oxaliplatin

Teva

Aminolevulinic Acid

Biomed Industries, Inc.

Analysis

Modality Breakdown

75%

Small molecule

46 of 61 classified programs — the dominant modality here.

25%ALL OTHERSMonoclonal antibody1220%Protein / enzyme35%

Small molecule leads; the ring shows all 61 classified programs, each share of the total. Modality classified for 98% of 63 pipeline programs.

Analysis

Trial Status

26

clinical trials

Completed11 · 42%
Terminated6 · 23%
Unknown status4 · 15%
Recruiting2 · 8%
Active, not recruiting1 · 4%
Withdrawn1 · 4%
Other1 · 4%

Clinical Trials

Trial Activity

26 trials

Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma
Recruiting·—·Phase 2·NCT07082439·27 enrolled
Master Protocol: An Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BAY 3771249 as Monotherapy or Combination With Other Cancer Treatments in Participants With Solid Tumors Harboring a KRAS G12D Mutation. Substudy Protocol: An Open-label, Multi-cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of BAY 3771249 as Monotherapy and in Combination With Cetuximab in Participants With Advanced/Metastatic Colorectal Adenocarcinoma Harboring a KRAS G12D Mutation
Recruiting·Bayer logoBayer·Phase 1·NCT07535112·130 enrolled
Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03599752·40 enrolled
An Open-label, Multicenter, Single-arm Clinical Study on the Use of Doxorubicin Liposome in Combination With CapOX and Bevacizumab Regimen for First-line Treatment of Advanced Colorectal Adenocarcinoma With SMAD4R361H/C Mutation.
Not yet recruiting·NNanfang Hospital, Southern Medical University·Phase 1/2·NCT06753721·13 enrolled
Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma
Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT00574171·29 enrolled
Exploration of Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab
Completed·CCentre Leon Berard·N/A·NCT01405430·63 enrolled
Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma
Completed·AAchieve Life Sciences·Phase 2·NCT00034190·28 enrolled
Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT）
Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT02390947·543 enrolled
Study of 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma
Completed·AAlberta Health services·Phase 2·NCT00168155·70 enrolled
Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma .
Completed·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT02788006·43 enrolled
DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma
Completed·Daiichi Sankyo logoDaiichi Sankyo·Phase 2·NCT00080834
Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma.
Completed·CCancer Advances Inc.·Phase 2·NCT02181465·11 enrolled
Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20)
Completed·—·Phase 2·NCT01900717·102 enrolled
A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)
Completed·Roche logoRoche·Phase 3·NCT02788279·363 enrolled
Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT02023333·11 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)